0001104659-17-007828.txt : 20170209 0001104659-17-007828.hdr.sgml : 20170209 20170209163423 ACCESSION NUMBER: 0001104659-17-007828 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170207 FILED AS OF DATE: 20170209 DATE AS OF CHANGE: 20170209 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Nabriva Therapeutics AG CENTRAL INDEX KEY: 0001641640 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: C4 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: LEBERSTRASSE 20 CITY: VIENNA STATE: C4 ZIP: 1110 BUSINESS PHONE: 43 (0)1 740 93-0 MAIL ADDRESS: STREET 1: LEBERSTRASSE 20 CITY: VIENNA STATE: C4 ZIP: 1110 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Broom Colin MD CENTRAL INDEX KEY: 0001289946 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37558 FILM NUMBER: 17588020 MAIL ADDRESS: STREET 1: 119 FRINGETREE DRIVE CITY: WEST CHESTER STATE: PA ZIP: 19380 4 1 a4.xml 4 X0306 4 2017-02-07 0 0001641640 Nabriva Therapeutics AG NBRV 0001289946 Broom Colin MD 1000 CONTINENTAL DRIVE SUITE 600 KING OF PRUSSIA PA 19406 0 1 0 0 Chief Executive Officer Stock Option 2017-02-07 4 A 0 26100 0.00 A 2027-02-06 Common Shares 26100 26100 D The exercise price is 79.63 Euro. This option was granted on February 7, 2017. Vesting will begin on February 28, 2017 and end on February 28, 2021. Twenty-five percent (25%) of the option will vest on February 28, 2018, and the remaining seventy-five percent (75%) will vest on a monthly pro-rata basis over the remaining vesting period. /s/ Gary L. Sender, by power of attorney 2017-02-09